This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Original paper

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

Volume: 103, Issue: 9, Pages: 1511 - 1517
Published: Jun 7, 2018
Abstract
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia treated with venetoclax to describe outcomes, toxicities, and treatment selection following venetoclax discontinuation. A total of 141 chronic lymphocytic leukemia patients were included (98%...
Paper Details
Title
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
Published Date
Jun 7, 2018
Volume
103
Issue
9
Pages
1511 - 1517
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.